Three Gene Mutations Linked to Epithelial Thyroid Cancers

This article originally appeared here.
Share this content:
Three Gene Mutations Linked to Epithelial Thyroid Cancers
Three Gene Mutations Linked to Epithelial Thyroid Cancers

(HealthDay News) – Cowden syndrome (CS)/CS-like patients with PTEN mutations, SDHx variations, and KLLN epimutations are at increased risk of epithelial thyroid cancers, according to a study published in the December 1 issue of the Journal of Clinical Endocrinology & Metabolism.

Joanne Ngeow, MB, BS, MRCP, from the Cleveland Clinic, and colleagues compared the incidence, clinical, and histological characteristics of epithelial thyroid cancers in 2,723 CS/CS-like individuals, with respect to their PTEN, SDHx, and KLLN status. All participants underwent comprehensive PTEN analysis. Those without PTEN mutations/variations, and with elevated manganese superoxide dismutase levels, underwent SDHx mutation analysis. A subset of participants without PTEN or SDHx mutation/deletion/variant/polymorphism were analyzed for KLLN epimutations. Demographic and clinical information, gene-specific thyroid cancer histologies, and adjusted standardized incidence rates were the main outcome measures.

The investigators found that 664 participants had thyroid cancer. The standardized incidence rates for thyroid cancer were 72, 63, and 45 for pathogenic PTEN mutations, SDHx variants, and KLLN epimutations, respectively. Pathogenic PTEN mutations were present in all of the six participants diagnosed under 18 years of age (16.7% of all PTEN mutations). In cases with PTEN mutations, follicular thyroid cancer was overrepresented compared with participants with SDHx and KLLN alterations. PTEN frameshift mutations were found in 31 and 17% of patients with and without thyroid cancer, respectively.

"CS/CS-like patients have elevated risks of follicular thyroid cancer due to PTEN pathogenic mutations and of papillary thyroid cancer from SDHx and KLLN alterations. Children presenting with thyroid cancer should be tested for PTEN mutations," the authors write.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs